Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It’s been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That’s likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of...
Good news for Ionis pipeline from this trial–upping target price to $65
Sometimes the importance of a clinical trial extends way beyond the specific drug under study. That’s the case with the Phase II data recently released by Ionis for FIXRx. The trial did show efficacy in the treatment of kidney disease. But the most important...Ionis Pharmaceuticals
Shares of Ionis Pharmaceuticals (IONS) no longer look like a falling knife and I’m adding them to my Jubak’s Picks portfolio https://jubakpicks.com/the-jubak-picks/ . One of the biggest cancer conferences of the year—that of the American Society of Clinical...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!